OKYO Pharma Limited's (LON:OKYO) CEO Gary Jacob tells Proactive's Andrew Scott it's time to take the company from development stage and into the clinic. Its flagship drug OK-113 inhibits Chemerin, one of a key group of cell surface receptors called G-protein coupled receptors (GPCRs), which play an important role in inflammation.
OKYO Pharma focused on getting its dry eye treatment into the clinic and to proof of concept
